HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on UroGen Pharma (NASDAQ:URGN) and maintained a price target of $54.
October 04, 2023 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma's stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $54.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $54 indicates the firm's continued confidence in UroGen Pharma's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100